LACTOLOGY FOUNDATION

Oxyphenonium bromide (ATC A03AB03) is a synthetic quaternary ammonium antimuscarinic antispasmodic that acts primarily on gastrointestinal smooth muscle and has the typical peripheral anticholinergic toxicity profile, with limited and poorly documented use in pregnancy and lactation and a generally cautionary stance during breastfeeding.medpedia.framar+4

Pharmacological class and indications

Oxyphenonium bromide belongs to the ATC class A03AB03 “synthetic anticholinergics, quaternary ammonium compounds,” used for functional gastrointestinal disorders. It is indicated as an adjunct in the treatment of gastric and duodenal ulcers, irritable bowel syndrome and other visceral spasms, and has also been used off‑label for biliary and renal colic, dysmenorrhea, and in some settings as a mydriatic eye drop.wikipedia+8

Mechanism of action and pharmacodynamics

Oxyphenonium is a peripheral antimuscarinic (anticholinergic) agent that competitively blocks acetylcholine at muscarinic receptors on smooth muscle, thereby reducing gastrointestinal tone, propulsive motility and secretions. In addition, it has a direct smooth muscle–relaxing effect, contributing to relief of visceral spasm and reduction of gastric acid secretion and excessive respiratory tract secretions.drugbank+4

Dosage and administration

Therapeutic oral dosing in adults is typically 25 mg (one tablet) one to three times daily, consistent with the WHO DDD of 25 mg by mouth. In children above approximately 8 years, lower doses such as half a tablet one to three times daily have been used, though pediatric use is off‑label in many jurisdictions and requires individualized assessment.atcddd.fhi+2

General adverse effects and toxicity

As a quaternary anticholinergic with atropine‑like activity, oxyphenonium produces typical peripheral anticholinergic adverse effects such as mydriasis, photophobia, blurred vision, dry mouth, decreased bronchial secretions, constipation and urinary retention. Other reported reactions include nausea and vomiting, flushing with warm dry skin, tachycardia and other arrhythmias, difficulty in swallowing and speaking, and, at higher doses or in susceptible patients, confusion or other central anticholinergic manifestations.wikipedia+5

Serious and overdose toxicity

In overdose or in patients with high anticholinergic burden, oxyphenonium can contribute to the anticholinergic toxidrome characterized by fever, agitation or delirium, severe tachycardia, hypertension, decreased bowel sounds and urinary retention. Management follows standard anticholinergic toxicity protocols: supportive care with airway, breathing and circulation stabilization, cardiac monitoring, decontamination with activated charcoal where appropriate, benzodiazepines for agitation or seizures, and consideration of physostigmine as a specific antidote in selected cases under experienced supervision.wwww.uomus+2

Contraindications and cautions (non‑lactation)

Oxyphenonium is contraindicated in patients with known hypersensitivity to the drug or other components, as well as in conditions where anticholinergics are generally avoided, such as narrow‑angle glaucoma, mechanical gastrointestinal obstruction, paralytic ileus, severe ulcerative colitis with risk of toxic megacolon, and urinary retention due to prostatic hypertrophy. Older or frail patients are particularly susceptible to anticholinergic adverse effects (constipation, urinary retention, dry mouth/eyes, sedation and cognitive impairment), and cumulative anticholinergic burden from concomitant drugs should be minimized.pubchem.ncbi.nlm.nih+3

Pregnancy safety overview

Data on oxyphenonium use in human pregnancy are scarce, and some product information indicates that animal studies have shown adverse fetal effects without adequate controlled human data. In the absence of robust evidence, use during pregnancy is generally discouraged unless potential maternal benefit clearly outweighs theoretical risks, with preference for better‑characterized alternatives where available.medex+2

Lactation pharmacology and exposure

Oxyphenonium is a permanently charged quaternary ammonium compound with limited lipid solubility, a property that typically restricts its transfer into breast milk and diffusion across biological membranes compared to tertiary anticholinergics. However, specific measurements of oxyphenonium concentrations in human milk or breastfed infants have not been found, so any estimate of relative infant dose must be extrapolated from class behavior and physicochemical properties rather than direct pharmacokinetic studies.drugcentral+2

Potential effects in breastfed infants

Given its predominantly peripheral antimuscarinic action, theoretical infant effects from significant exposure would include decreased gastrointestinal motility (constipation), urinary retention, reduced secretions and possible pupillary dilation, especially in neonates or preterm infants. Because clinical reports in breastfed infants are lacking, the true risk is unknown, but caution is warranted particularly in the early neonatal period, in premature infants, and in infants with underlying gastrointestinal or urinary tract disorders.drugs.ncats+4

Potential effects on lactation and milk production

Anticholinergic agents may reduce secretions in general, but there is no direct evidence that oxyphenonium significantly diminishes human milk production at therapeutic doses. Nevertheless, in mothers struggling with borderline milk supply or in the immediate postpartum period, cumulative anticholinergic burden and dehydration (secondary to dry mouth and reduced fluid intake) might theoretically contribute to reduced lactation performance, so monitoring and supportive measures are advisable.wikipedia+1

Toxicology–lactation risk assessment

From a toxico‑lactologic perspective, oxyphenonium represents a drug with limited systemic bioavailability to the infant due to its quaternary structure but with negligible direct evidence base in breastfeeding. In healthy term infants and short‑term maternal use at standard doses, overall risk is probably low but not quantifiable, so the drug might be considered compatible with breastfeeding under close clinical observation, whereas prolonged or high‑dose therapy should prompt consideration of more extensively studied alternatives.drugcentral+2

Clinical use recommendations in breastfeeding

When oxyphenonium is considered for a breastfeeding mother, it should be prescribed at the lowest effective dose for the shortest duration, with avoidance of multiple concomitant anticholinergics to limit cumulative toxicity. The infant should be monitored for signs of anticholinergic effects (poor feeding, constipation, reduced urine output, unusual drowsiness, irritability or visual disturbances), and if such signs emerge, clinicians should reassess therapy and consider drug discontinuation or substitution.derbyshiremedicinesmanagement+5

Situations requiring avoidance or specialist consultation

Use of oxyphenonium in breastfeeding should be avoided or undertaken only with specialist input when the infant is premature, has chronic gastrointestinal or urinary diseases, or is receiving other medications with anticholinergic properties. In such high‑risk scenarios, alternative antispasmodics with better lactation safety documentation are generally preferable, and if oxyphenonium is unavoidable, a detailed risk–benefit discussion and shared decision‑making process with the mother are essential.wwww.uomus+5